2025361752

About This Trademark

This device mark (application number 2025361752) is a 00 trademark on the Japan Patent Office register, filed by Ultragenyx Pharmaceutical Inc. on 18 September 2025, with registration granted on 14 April 2025.

This mark is recorded under multiple classes: Class 5 (pharmaceuticals & medical preparations); Class 42 (scientific, IT & design services); Class 44 (medical, veterinary & beauty services), specifically covering: Pharmaceutical preparations for the treatment of genetic, central nervous system, and lysosomal storage diseases and disorders; gene therapy products for the treatment of genetic, central nervous system, and lysosomal storage diseases and disorders, namely, virus vector-based gene therapy preparations for intravenous delivery.; Pharmaceutical, scientific, and medical research and development in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; scientific research in the nature of conducting clinical trials for others in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; scientific and medical research, namely, compiling and sharing of patient data for research purposes in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; providing medical and scientific research information in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; providing medical research and scientific research information in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; pharmaceutical, scientific, and medical research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of gene therapy, genetic, central nervous system, and lysosomal storage diseases and disorders; biomedical research in the field of gene therapy design and delivery; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; scientific research in the nature of conducting clinical trials for others in the field of gene therapy design and delivery.; Providing medical services in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; medical consulting services in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; healthcare services, namely, providing an online database of medical and healthcare information in the field of genetic, central nervous system, and lysosomal storage diseases and disorders, featuring inputting and collection of data and information on genetic, central nervous system, and lysosomal storage diseases and disorders for screening, diagnosis and treatment purposes (Term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); medical information services in the nature of providing a database in the field of genetic, central nervous system, and lysosomal storage disease and disorder information based on collected patient data and information all for treatment and diagnostic purposes (Term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of genetic, central nervous system, and lysosomal storage diseases and disorders.